Glucotrack, Inc. · NASDAQ:GCTK
Glucotrack — Investor Presentation (April 2026)
23 slides from Glucotrack's investor presentation, Apr 30, 2026
Slide 1: Glucotrack: Advancing Diabetes Management
Glucotrack © Advancing | Diabetes - Manage —— Introducing _ Continuous: = April 2026 7 _ a © Copyright 2026. All rights reser
Slide 2: Important Disclaimers
IMPORTANT DISCLAIMERS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this presentation that are not statements of historical fact may be deemed to be forward-looking statements. Without limitin
Slide 3: Redefining Glucose Monitoring
REDEFINING GLUCOSE MONITORING , ener . — QW Implantable ~ Continuous Glucose Monitoring (S
Slide 4: CBGM: Advanced Monitoring, Expanding Market
CBGM: ADVANCED MONITORING, EXPANDING MARKET : e * Py Pyauosrion Seam oy First-in-human safety | demonstrated Feasibility study complete (OUS) 6 IDE process initiated ISO 13485 certified Direct Blood Sensing Fully Implantable _ ~~ 3-Year Longevity No Wearables ’ Glucotrack. Reference: 1.Close Concers
Slide 5: An Experienced Team
AN EXPERIENCED TEAM \ Paul V. Goode, PhD ee =) Drinda Benjamin, MBA Glucose monitoring Implantable cardiac devices Glucose monitoring Insulin delivery A JP Thrower, PhD ) Ted Williams ~ Glucose monitoring € ~ Patient monitoring vary pexcom © intuity EndoSt\m Medtronic ©) Abbott CARDIUM " BSOoRt Guid
Slide 6: Diabetes Innovation Can't Wait
DIABETES INNOVATION CAN'T WAIT The growing burden is placing enormous strain on healthcare resources @ @p 2 2x higher risk ~40% develop >25% spending Heart disease or stroke Chronic kidney disease Linked to diabetes sit ‘ \ 1 in 10 adults 40 million Americans \COC/National Center Glucotrack:
Slide 7: CGM Adoption Is Accelerating
CGM ADOPTION IS ACCELERATING Yet More Than Half the Market Remains Untapped Diabetes Technology Quarterly Revenue (M)' $6,000 5 po $13.4B clobal cem Market (2025) Ses $5,500-] —= CGM ~50% of revenue generated in US $4,500 Q4 2025 revenue of $3.6B $3,500 +12% year over year $2,500 4 $1,500 4 $1,000 s
Slide 8: CGM Focus Is Shifting to Lower-Risk
CGM FOCUS IS SHIFTING TO LOWER-RISK Adoption is expanding beyond the highest-need populations Diabetes Segments by Size & Penetration (M)' Patients with daily monitoring needs & broad insurance coverage 5 4 A 15 2 10 , 0 0 Type 1 Type 2 Insulin Intensive Type 2 Basal Type 2 Hypo Risk Type 2 Non-Insu
Slide 9: CGM was a breakthrough, but... The technology still has limits
CGM was a breakthrough, but... CGM Benefits Continuous Monitoring 24/7 wearable sensor Glucose trends ionable Insights ws direction and rate of glucose change stablished Standard Broad clinical validation Widely reimbursed pyright 2026, All rights reserved. Glucotrack, THE TECHNOLOGY STILL HAS LIMIT
Slide 10: What Patients Want, But Are Still Not Getting
WHAT PATIENTS WANT, BUT ARE STILL NOT GETTING Unaddressed patient needs growing in importance 70% 5 [ 2018 BB 2025 60% _| 50% | 40% 30% 20% 10% 44% 9 57% 39% § 40% 21% § 37% 0% Longer sensor wear Shorter sensor Better accuracy ‘Smaller, thinner Better sensor Longer transmission ‘warmup time CGM sens
Slide 11: The Glucotrack Solution: A Breakthrough CBGM System
The Glucotrack Solution: A BREAKTHROUGH CBGM SYSTEM A first-of-its-kind system that combines Designed from FDA-approved components the best of glucose monitoring and cardiac and adopted techniques to accelerate monitoring technology in one device development and reduce regulatory risk Axillary Vein
Slide 12: Cardiology Implant Specialists Already See Patients with Diabetes
CARDIOLOGY IMPLANT SPECIALISTS ALREADY SEE PATIENTS WITH DIABETES Patients with Diabetes Seen by Specialist in Past 12 Months 50% DIABETES ISA CARDIOMETABOLIC ~ DISEASE Strongly associated with Atherosclerotic Cardiovascular Disease (ASCVD), heart failure, and stroke Cardiologists increasingly invol
Slide 13: Putting Risk in Perspective
PUTTING RISK IN PERSPECTIVE The real threat is uncontrolled diabetes Implant complications are very low’ Glucotrack’s CBGM is even less complex » Simpler procedure + Smaller lead * Shorter entry 40 Implanting Risk (%) 30 20 10 0.4% 0.6% 1.0% 1.2% 1.3% 1.4% 0 en Vascular Thrombosis Bleeding Bleeding/
Slide 14: What Makes Our CBGM Different?
WHAT MAKES OUR CBGM DIFFERENT? Implant once. Monitor for years. Designed to deliver up to 3 years of continuous monitoring with ‘ blood-true accuracy without no external wearables or daily upkeep. LONGEVITY DESIGN ACCURACY One sensor. No skin adhesive. Blood-true sensing. Three years. No bulky weara
Slide 15: CGM Focus Is Shifting to Lower-Risk
CGM FOCUS IS SHIFTING TO LOWER-RISK Adoption is expanding beyond the highest-need populations Diabetes Segments by Size & Penetration (M)' 30 A . 7 oe 25 Patients with daily monitoring needs & broad insurance coverage 20 15 10 Faure} 7 2M 2.5M 0 Type 1 Type 2 Insulin Intensive Type 2 Basal Type 2 Hy
Slide 16: CBGM Targeted Populations
CBGM TARGETED POPULATIONS Four targeted segments rely on CGM daily ~11.4M people with clinical consensus and broad coverage 2017: CMS coverage of CGM for T1D 2021: ADA recommends CGM as standard of care 2023: CMS coverage of CGM for T2D * intensive insulin therapy + basal insulin + tisk of hypoglyce
Slide 17: Large Market Opportunity for CBGM
LARGE MARKET OPPORTUNITY FOR CBGM According to research, ~1 in 4 TAM patients are willing to receive an implant | Wil rely on CGM daily WHY CBGM MATTERS Reduces CGM “tech burnout” Increases long-term adherence _Improves confidence Patients frequently report fatigue from sensor Lower daily management
Slide 18: First-in-Human Study Demonstrates Feasibility
FIRST-IN-HUMAN STUDY DEMONSTRATES FEASIBILITY Prototype implant demonstrated reliable continuous glucose monitoring Study Overview 36-hour glucose monitoring including FST 1; MARD=5.9% * 8 participants with T1D or T2D using intensive insulin * Sensor lead implanted with — CBGM Glucose © Blood Glucos
Slide 19: Early Data Show Strong Sensor Accuracy
EARLY DATA SHOW STRONG SENSOR ACCURACY Performance vs reference blood glucose measurements Continuous Measurements vs Reference 400 350 MARD 7.7% across 122 matched glucose pairs 300 Measurement Glucose (mg/dL) = © Commercial CGM °CBGM ~~ Perfect fit line 0 50 100 150 200 250 300 350 400 Reference (
Slide 20: Clinical and Regulatory Timeline
CLINICAL AND REGULATORY TIMELINE Leveraging proven regulatory strategies - DeNovo 510k Pathway FDA DeNovo 510k submission (1-year data) US Pilot IDE approval US Pivotal submission US Pivotal begins US Pivotal US Pilot IDE US Pilot IDE pert US Pivotal 1 year | FDA Approval begins 1-Year Data complete
Slide 21: Engineered for What Patients Want
ENGINEERED FOR WHAT PATIENTS WANT (and Wearable CGMs Can't Deliver) ww Unsurpassed longevity Placed once every 3 years 20-minute outpatient procedure ww Wearable-free comfort Fully implantable design No on-body devices ww Real-time blood glucose readings Uses blood-true sensing Greater accuracy and
Slide 22: Poised for Impact. Positioned for Growth.
POISED FOR IMPACT. POSITIONED FOR GROWTH. (@ Glucotrack is pioneering a fully implantab designed to overcome the limitations of wearableCGMs : MOMENTUM ADOPTION CONVERSION 1 SCALE Unlock adoption among Capitalize on strong . Convert CGM users Expand through regulatory the >50% of patients not diabet
Slide 23: Thank You
Glucotrack G Thank You 23. © Copyright 2026. All rights reserved, Glucotrack.